Eladio Vega, 37, was sentenced July 24 to 87 months in prison and three years of supervised release after pleading guilty to one count of conspiracy to traffic misbranded and adulterated drugs.
Mr. Vega is the 15th individual connected to the investigation to plead guilty and was the 17th to be indicted.
According to the FDA, the company’s “scheme involved a division of labor, in which street-level dealers obtained the medicines and supplied them to participants who inspected, cleaned, and packaged the drugs for shipment to others with established pharmaceutical wholesale companies,” a July 25 release states. “The wholesale company owners prepared fraudulent documentation, falsely representing that legitimate drug manufacturers had provided the medications to them. In fact, the suppliers had acquired the drugs through health care fraud, theft or burglary, or by buying the medications from patients who obtained prescriptions but chose to sell them rather than take their medicines.”
When profits were made, steps were taken by individuals involved in the scheme to route the money through several shell companies to conceal what was going on.
The corporation defendant was forced to pay a penalty of $78 million for its role in the money laundering conspiracy.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.